Agios to Participate in September Investor Conferences

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced that the company is scheduled to present at the following September investor conferences:

  • Wells Fargo Healthcare Conference on Wednesday, September 7, 2022 at 8:35 a.m. ET; and
  • Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 4:50 p.m. ET.

Live webcasts of the presentations can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.agios.com. Replays of the webcasts will be archived on the Agios website for at least two weeks following each presentation.

About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare and genetically defined diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company’s leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with active and planned programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has multiple investigational therapies in preclinical development and an industry-leading research team with unmatched expertise in cellular metabolism and genetics. For more information, please visit the company’s website at www.agios.com.

Contacts

Investors:
Holly Manning, 617-844-6630
Senior Director, Investor Relations
Holly.Manning@agios.com

Media:
Jessica Rennekamp, 857-209-3286
Senior Director, Corporate Communications
Jessica.Rennekamp@agios.com 

Staff

Recent Posts

English Version of “Long-term Care Tech Portal” Newly Launched, Introducing Latest Care and Age Tech in Japan

TOKYO, March 24, 2025 /PRNewswire/ -- The long-term care robot portal site management office released…

60 minutes ago

PurDentix Alerts Consumers About Fake Listings as Counterfeit Supplement Market Expands

SEATTLE, March 24, 2025 /PRNewswire/ --  The surge in online supplement sales has led to…

60 minutes ago

Chang Gung Memorial Hospital Advances Minimally Invasive Surgery with Robotic Technology

Achieves International Recognition with HIMSS Award for Excellence in Smart Healthcare TAOYUAN, March 23, 2025…

7 hours ago

Leveling the Playing Field: Advocating for Women in Science & Research

NEW YORK, March 23, 2025 /PRNewswire/ -- Today Mediplanet launches their Women in Research campaign, aimed at…

19 hours ago

Ever Joint Benefits: How This Supplement Supports Flexibility and Weight Loss

TALLMADGE, Ohio, March 22, 2025 (GLOBE NEWSWIRE) -- Weight management remains a paramount concern for…

22 hours ago

Best Steroids For Bodybuilding (Muscle Growth & Bulking) From CrazyBulk in 2025

NEW YORK, March 22, 2025 (GLOBE NEWSWIRE) -- “CrazyBulk Stacks. Want the best results? Then…

2 days ago